RT Journal Article
SR Electronic
T1 632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A722
OP A722
DO 10.1136/jitc-2023-SITC2023.0632
VO 11
IS Suppl 1
A1 Li, Tianhong
A1 Chen, Shuai
A1 Ma, Weijie
A1 Toomey, Kyra A
A1 Long, Siqi
A1 Lu, Tingting
A1 Pineda, Colleen
A1 Molnar, Laura
A1 Garcia, Leslie
A1 Tam, Kit
A1 Verma, Rashmi
A1 Zhou, Chihong
A1 Ogilhara, Nancy
A1 Babich, Michael
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A722.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.